

## PRESS RELEASE Stockholm December 19, 2022

### **ADDvise receives order worth USD 1.5 million**

ADDvise Group AB's subsidiary Poly Pharmaceuticals Inc has received an order from Wellgistics, a pharmaceutical wholesale distributor delivering to independent pharmacies in USA. The order is worth approximately USD 1.5 million. The order consists of delivery of the dietary supplemental Folite, developed and manufactured by Poly Pharmaceuticals. Delivery will take place immediately.

### **For further information, please contact:**

Rikard Akhtarzand, CEO  
+46 765-25 90 71  
rikard.akhtarzand@addvisigroup.se

### **Important information:**

*This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on December 19, 2022, at 16:40 CET.*

### **About ADDvise Group**

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at [www.addvisigroup.com](http://www.addvisigroup.com).